AbbVie (ABBV) Q3 FY2021 earnings: revenue $14.3 billion, up 11.2% on the year
AbbVie Inc. (ABBV) reported revenue of $14.3 billion for Q3 FY2021, the quarter ended 30 September 2021, up 11.2% on the same quarter a year earlier. Net income was $3.2 billion, up 37.7% on the year, and diluted earnings per share $1.78. The figures are the company's own, from the 10-Q it filed with the SEC on 2 November 2021.
Revenue
$14.3 billion
+11.2% on the year · +2.7% on the quarter
Q4 FY2019Q3 FY2021
Operating margin
30.0%
25.2% a year earlier
Q4 FY2019Q3 FY2021
Net income
$3.2 billion
+37.7% on the year · +315.0% on the quarter
Q4 FY2019Q3 FY2021
Diluted EPS
$1.78
+38.0% on the year · +323.8% on the quarter
Q4 FY2019Q3 FY2021
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q3 FY2021
Q2 FY2021
Q3 FY2020
On the quarter
On the year
Last 8 quarters
Revenue
14,342
13,959
12,902
+2.7%
+11.2%
Cost of revenue
4,390
4,523
5,050
-2.9%
-13.1%
Gross profit
9,952
9,436
7,852
+5.5%
+26.7%
Gross margin
69.4%
67.6%
60.9%
Research and development
1,661
1,767
1,706
-6.0%
-2.6%
Selling, general and administrative
3,083
3,164
2,846
-2.6%
+8.3%
Operating income
4,306
4,441
3,255
-3.0%
+32.3%
Operating margin
30.0%
31.8%
25.2%
Interest expense
596
615
630
-3.1%
-5.4%
Pre-tax income
3,688
1,163
2,500
+217.1%
+47.5%
Income tax
508
394
187
+28.9%
+171.7%
Effective tax rate
13.8%
33.9%
7.5%
Net income
3,179
766
2,308
+315.0%
+37.7%
Net margin
22.2%
5.5%
17.9%
Diluted EPS
$1.78
$0.42
$1.29
+323.8%
+38.0%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.
Cash flow
$ million
Q3 FY2021
Q2 FY2021
Q3 FY2020
On the quarter
On the year
Last 8 quarters
Operating cash flow
7,935
4,890
5,830
+62.3%
+36.1%
Capital expenditure
217
195
217
+11.3%
0.0%
Free cash flow
7,718
4,695
5,613
+64.4%
+37.5%
Free cash flow margin
53.8%
33.6%
43.5%
Cash from investing
-615
-242
-1,149
Cash from financing
-3,643
-5,884
-2,814
Depreciation and amortisation
2,123
2,201
2,275
-3.5%
-6.7%
Depreciation
223
201
175
+10.9%
+27.4%
Share-based compensation
135
159
162
-15.1%
-16.7%
Buybacks
6.0
10.0
20.0
-40.0%
-70.0%
Dividends paid
2,315
2,310
2,100
+0.2%
+10.2%
Diluted shares, weighted
1,777m
1,776m
1,774m
+0.1%
+0.2%
Shares outstanding at period end
1,768m
1,767m
1,765m
+0.0%
+0.1%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2021
Q2 FY2021
Q3 FY2020
On the quarter
On the year
Last 8 quarters
Shareholders' equity
13,550
12,569
15,270
+7.8%
-11.3%
Non-controlling interest
27.0
25.0
19.0
+8.0%
+42.1%
Short-term borrowings
n/a
17.0
54.0
Debt
80,721
74,237
82,282
+8.7%
-1.9%
Other liabilities
54,560
61,124
51,996
-10.7%
+4.9%
Total liabilities and equity
148,858
147,972
149,621
+0.6%
-0.5%
Fixed assets
5,130
5,161
4,986
-0.6%
+2.9%
Goodwill
32,296
32,398
42,801
-0.3%
-24.5%
Intangible assets
77,456
79,340
74,643
-2.4%
+3.8%
Investments
339
320
306
+5.9%
+10.8%
Cash and equivalents
12,182
8,546
7,890
+42.5%
+54.4%
Receivables
9,281
9,914
8,416
-6.4%
+10.3%
Inventory
3,094
3,386
3,474
-8.6%
-10.9%
Other assets
9,080
8,907
7,105
+1.9%
+27.8%
Total assets
148,858
147,972
149,621
+0.6%
-0.5%
Questions
What was AbbVie's revenue in Q3 FY2021?
AbbVie (ABBV) reported revenue of $14.3 billion for Q3 FY2021, the quarter ended 30 September 2021, up 11.2% on the same quarter a year earlier.
How much did AbbVie earn in Q3 FY2021?
Net income for Q3 FY2021 was $3.2 billion, up 37.7% on the year, and diluted earnings per share $1.78.
When did AbbVie report Q3 FY2021 results?
AbbVie filed its 10-Q for the quarter ended 30 September 2021 with the SEC on 2 November 2021.
Each quarter as filed, linked to its filing. Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2021, filed 2 November 2021: the filing.